Interleukin-37 expression and its potential role in oral leukoplakia and oral squamous cell carcinoma.

Interleukin-37 expression and its potential role in oral leukoplakia and oral squamous cell carcinoma.
复制标题

IL-37在口腔白斑和口腔鳞状细胞癌中的表达及其潜在作用

DOI:
10.1038/srep26757
复制
发表时间:
2016-05-26
期刊:
影响因子:
4.6
通讯作者:
Chen Q
Chen Q
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Lin L;Wang J;Liu D;Liu S;Xu H;Ji N;Zhou M;Zeng X;Zhang D;Li J;Chen Q

文献摘要

被引文献

相似文献

据报道,白细胞介素 37 (IL-37) 在先天免疫反应中发挥着重要作用,并与多种癌症有关。然而,IL-37 与口腔粘膜癌发生之间关联的研究尚未明确。该研究的目的是评估 IL-37 的表达并探讨其在口腔粘膜癌发生中的作用。 IL-37的表达从正常对照(NC)到口腔白斑(OLK)和口腔鳞状细胞癌(OSCC)增加。此外,有和没有轻度/中度不典型增生的 OLK 评分之间存在统计学上的显着差异(P<0.001)。此外,有淋巴结转移的OSCC中IL-37的表达低于无转移的OSCC(P<0.01)。此外,RAW264.7细胞中IL-37的过度表达显着减少了伪足、空泡化以及IL-6、TNF-α和IL-1β的表达。最后,我们发现IL-37及其受体IL-18Rα而非其结合伙伴IL-18BP在口腔粘膜癌变的不同阶段具有相似的组织定位和表达趋势。总体而言,IL-37可作为早期口腔肿瘤发生和癌前病变恶变风险评估的生物标志物。
Interleukin 37 (IL-37) has been reported to play a significant role in innate immune response and to be involved in several kinds of cancers. However, the investigation of association between IL-37 and oral mucosa carcinogenesis hasn't been clearly established. The aim of the study was to assess IL-37 expression and explore its role in oral mucosa carcinogenesis. The expression of IL-37 increased from normal control (NC) to Oral leukoplakia (OLK) and oral squamous cell carcinoma (OSCC). Moreover, statistically highly significant difference was present between scores of OLK with and without mild/moderate dysplasia (P < 0.001). In addition, IL-37 expression was lower in OSCC with lymph node metastasis than those without metastasis (P < 0.01). What’s more, overexpression of IL-37 in RAW264.7 cells remarkably reduced the pseudopodia, vacuolization and the expression of IL-6, TNF-α, and IL-1β. Finally, we found IL-37 and its receptor IL-18Rα but not its binding partner IL-18BP have similar tissue location and expression trend in different stages of oral mucosa carcinogenesis. Overall, IL-37 can be used as a biomarker for early oral tumorigenesis and for malignant transformation risk assessment of premalignant lesions.